Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source - Episode 1
Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause
Published on:
Anjali Tiku Owens, MD, examines the unmet needs in treating obstructive hypertrophic cardiomyopathy (oHCM) and explores how novel Cardiac Myosin inhibitors (CMIs) address the root cause of the condition.
- The treatment of obstructive hypertrophic cardiomyopathy (oHCM) has a high level of unmet needs, can you discuss these with us?
- How do novel cardiac myosin inhibitors (CMIs) target the underlying cause of oHCM?
2. What has the impact of CMI’s been on the management of oHCM?
- Complements (first line) standard of care
- Addresses the root cause of oHCM
- Narrowing the substantial gap between effective medical therapy and the more definitive invasive treatments like alcohol septal ablation and surgical myectomy.
